Load of waffle | Uranium is hot | Contract wins
News and updates covered here include a questionable justification for the sale of two fast-growing companies by an AIM listed group. Elsewhere, there were significant contract wins for others and a hefty funds raise for one popular company. Read on here for more on this and other news.
hVIVO: another contract - it’s all about the execution hVIVO (AIM: HVO), a specialist contract research organisation (CRO) and apparent “world leader” in testing infectious and respiratory disease products using human challenge clinical trials, announced a £6.8m contract with a leading pharmaceutical company based in Asia Pacific. The contract covers the testing of its respiratory syncytial virus ("RSV") antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model and will take place at hVIVO’s specialist quarantine facilities in Whitechapel. The study is expected to start in the first half of 2024, with revenue mostly recognised in 2024. As part…